Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Deerfield_Management
|
| gptkbp:CEO |
gptkb:Christine_Ann_Miller
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:filedForBankruptcy |
2019
|
| gptkbp:focusesOn |
antibiotics
|
| gptkbp:formerName |
gptkb:Rib-X_Pharmaceuticals
|
| gptkbp:foundedYear |
2000
|
| gptkbp:headquartersLocation |
gptkb:Morristown,_New_Jersey,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Melinta Therapeutics
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:product |
gptkb:Vabomere
gptkb:Baxdela gptkb:Minocin gptkb:Orbactiv |
| gptkbp:specializesIn |
infectious diseases
|
| gptkbp:stockSymbol |
MLNT
|
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:website |
https://www.melinta.com/
|
| gptkbp:bfsParent |
gptkb:Vabomere
|
| gptkbp:bfsLayer |
6
|